[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
[引用][C] Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced …
PN Ding, SJ Lord, V Gebski, M Links, V Bray… - Journal of Thoracic …, 2017 - cir.nii.ac.jp
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of
Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell …
Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell …
Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated …
PN Ding, SJ Lord, VJ Gebski… - Journal of …, 2017 - researchdirect.westernsydney.edu …
Introduction: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
[PDF][PDF] Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced …
M Links, V Bray, RJ Gralla, JCH Yang, CK Lee - 2016 - researchgate.net
Introduction: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advancedEGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advancedEGFR-mutated NSCLC. Estimating differences in toxicity between …
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR …
PN Ding, SJ Lord, V Gebski, M Links… - Journal of Thoracic …, 2017 - research.bond.edu.au
Methods We performed a meta-analysis of randomized trials that compared EGFR TKI
therapy against chemotherapy or placebo. We extracted data from the EGFR TKI arm for …
therapy against chemotherapy or placebo. We extracted data from the EGFR TKI arm for …
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR …
PN Ding, SJ Lord, V Gebski, M Links… - Journal of Thoracic …, 2016 - europepmc.org
Methods We performed a meta-analysis of randomized trials that compared EGFR TKI
therapy against chemotherapy or placebo. We extracted data from the EGFR TKI arm for …
therapy against chemotherapy or placebo. We extracted data from the EGFR TKI arm for …
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR …
PN Ding, SJ Lord, V Gebski, M Links… - Journal of Thoracic …, 2017 - einstein.elsevierpure.com
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR …
PN Ding, SJ Lord, V Gebski, M Links, V Bray… - Journal of Thoracic …, 2017 - jto.org
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR …
PN Ding, SJ Lord, V Gebski, M Links… - Journal of thoracic …, 2017 - pubmed.ncbi.nlm.nih.gov
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …